Press Releases

August 05, 2020
Immunomedics Announces Second Quarter 2020 Results and Provides Corporate Update
July 27, 2020
Immunomedics to Report Second Quarter 2020 Results and Host Conference Call and Webcast on August 5, 2020
July 13, 2020
Immunomedics Expands Collaboration with Roche Evaluating TrodelvyTM
July 06, 2020
Immunomedics Announces Positive Results from Phase 3 ASCENT Study of TRODELVYTM
July 02, 2020
Immunomedics to Host Conference Call and Webcast on July 6, 2020 to Provide Clinical Update
May 28, 2020
Immunomedics to Participate in Upcoming Healthcare Conferences
May 27, 2020
Immunomedics Announces Leadership Change and Provides Business Update Amid COVID-19
May 13, 2020
Immunomedics to Present New Trodelvy Data in Non-Breast Indications at the 2020 ASCO Virtual Meeting
May 07, 2020
Immunomedics to Participate in BofA Securities 2020 Healthcare Conference
May 06, 2020
Immunomedics Reports First Quarter 2020 Results and Provides Corporate Update
May 04, 2020
Immunomedics Announces Commercial Availability of Trodelvy in the United States
May 01, 2020
Immunomedics Announces Closing of Public Offering of Common Stock
April 30, 2020
Immunomedics to Report First Quarter 2020 Results and Host Conference Call and Webcast on May 6, 2020
April 28, 2020
Immunomedics Announces Pricing of Public Offering of Common Stock
April 27, 2020
Immunomedics Announces Proposed Public Offering of Common Stock
April 22, 2020
FDA Grants Accelerated Approval for Immunomedics’ Trodelvy in Previously-Treated Metastatic Triple Negative Breast Cancer
April 07, 2020
FDA Grants Fast Track Designation to Sacituzumab Govitecan for Metastatic Urothelial Cancer
April 06, 2020
Immunomedics Announces ASCENT Study to be Stopped for Compelling Efficacy
Immunomedics Announces Executive Leadership Changes and the Appointment of Harout Semerjian as President and CEO
April 03, 2020
Immunomedics to Host Conference Call and Webcast on April 06, 2020 to Provide Clinical and Corporate Update
March 25, 2020
Immunomedics Provides COVID-19 Business Continuity Update, Affirms Strategic Priorities, and Shares R&D and Regulatory Update
February 27, 2020
Immunomedics Appoints Robert W. Azelby to Board of Directors
Immunomedics Reports Fourth Quarter and Full Year 2019 Results and Provides Corporate Update
February 25, 2020
Immunomedics to Participate in Upcoming Healthcare Conferences
February 20, 2020
Immunomedics to Report Results for the Fourth Quarter and Full Year 2019 and Host Conference Call and Webcast on February 27, 2020
February 14, 2020
Immunomedics Appoints Dr.Loretta Itri Chief Medical Officer
February 06, 2020
Immunomedics to Participate in Guggenheim Healthcare Talks | Oncology Day